$COTI
CORETAG, INC.

2023 Q3 Form 10-Q Financial Statement

#000101738623000275 Filed on July 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.680K
YoY Change -69.02%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.680K $9.071K
YoY Change -69.02% -28.23%
Operating Profit -$9.071K
YoY Change -28.23%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.680K
YoY Change -69.02%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.680K -$9.071K
YoY Change -69.02% -28.23%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 225.0M shares 225.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets $0.00 $0.00
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.450K $12.34K
YoY Change -46.62% 26.49%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $46.42K $40.60K
YoY Change 221.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $69.67K $65.99K
YoY Change 76.13% 138.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $69.67K $65.99K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $69.67K $65.99K
YoY Change 76.13% 138.18%
SHAREHOLDERS EQUITY
Retained Earnings -$144.4K -$140.7K
YoY Change 26.43% 37.52%
Common Stock $22.50K $22.50K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$69.67K -$65.99K
YoY Change
Total Liabilities & Shareholders Equity $0.00
YoY Change -100.0%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.680K -$9.071K
YoY Change -69.02% -28.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$13.24K
YoY Change -8.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.15K
YoY Change -22.73%
NET CHANGE
Cash From Operating Activities -13.24K
Cash From Investing Activities
Cash From Financing Activities 11.15K
Net Change In Cash -2.090K
YoY Change 6866.67%
FREE CASH FLOW
Cash From Operating Activities -$13.24K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001624140
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q2 us-gaap Assets
Assets
usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56293
dei Entity Registrant Name
EntityRegistrantName
Nine Alliance Science & Technology Group
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
35-2515740
dei Entity Address Address Line1
EntityAddressAddressLine1
7325 Oswego Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Liverpool
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
13090
dei City Area Code
CityAreaCode
(315)
dei Local Phone Number
LocalPhoneNumber
451-7515
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
225000000 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
68 usd
CY2022Q3 us-gaap Assets
Assets
68 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12339 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15830 usd
CY2023Q2 jmkj Accounts Payable Related Party
AccountsPayableRelatedParty
10750 usd
CY2022Q3 jmkj Accounts Payable Related Party
AccountsPayableRelatedParty
7000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2303 usd
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2303 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
40597 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
14424 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
65989 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39557 usd
CY2023Q2 us-gaap Liabilities
Liabilities
65989 usd
CY2022Q3 us-gaap Liabilities
Liabilities
39557 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
225000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
225000000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
22500 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
22500 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52194 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52194 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140683 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114183 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-65989 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-39489 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4719 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1570 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11957 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4865 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
4352 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
11069 usd
us-gaap Professional Fees
ProfessionalFees
14543 usd
us-gaap Professional Fees
ProfessionalFees
17141 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9071 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12639 usd
us-gaap Operating Expenses
OperatingExpenses
26500 usd
us-gaap Operating Expenses
OperatingExpenses
22006 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9071 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12639 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26500 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22006 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9071 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12639 usd
us-gaap Net Income Loss
NetIncomeLoss
-26500 usd
us-gaap Net Income Loss
NetIncomeLoss
-22006 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
225000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
225000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
225000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
225000000 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-39489 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-4859 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-44348 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12570 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-56918 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-9071 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-65989 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-34293 usd
CY2021Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
28694 usd
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4445 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10044 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4922 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-14966 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12639 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-27605 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
26500 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
22006 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3491 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2908 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3750 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-9496 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26241 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28594 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28694 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
26173 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26173 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28694 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
100 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zhfdfloYGFUl" style="font: 9pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">NOTE 1 – NATURE OF OPERATIONS</span></b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nine Alliance Science and Technology Group (the “Company”) was incorporated as Paramount Supply Inc. and established under the Corporation Laws of the State of Nevada on September 12, 2014. On September 29, 2017, the Company filed a Certificate of Amendment changing the name from “Paramount Supply Inc.” to “Nine Alliance Science and Technology Group”. The Company was formed for the purpose of marketing and distributing ladies fashion handbags. At the end of 2017 the Company became dormant and ceased all business operations.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 27, 2020, a motion and application was made to appoint a Custodian of the Company based on prior management abandoning its responsibilities to continue making filings at the Nevada Secretary of State’s office and for failing to hold a stockholders’ meeting in over 3 years and otherwise failing to keep current in its obligations to the Company.  Upon motion and application to the District Court, Clark County Nevada, the Court granted the request for Custodian for the Company (“Custodian”).   Upon granting the motion, the Court issued an Order acknowledging that the Custodian has performed all of the duties that had been required of it and the management of the Company will revert exclusively to the officers and directors appointed by the Custodian. In the Revival of the Company, Investment Reserves Series, as the Custodian of the Company, appointed Joseph Passalaqua as CEO, CFO and Secretary. As of the period ended, June 30, 2023, Joseph Passalaqua is CEO, CFO and Secretary.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 2, 2023 the Company filed with the State of Nevada to change the Company name to Coretag, Inc. , and a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230601__20230602_ziZ0FtzVlHqj">2,500-to-1</span> Reverse Stock Split of the Issued and Outstanding Shares of Common Stock. The Board Resolutions and Consents have been provided to FINRA and are pending approval.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 6, 2023 the Company entered into a Common Stock Purchase Agreement with Coretag Holding AG, a German Public Limited Company, following the Closing date, when the name change and reverse split receive approval, the Company will file a Super 8K with the SEC.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2,500-to-1
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_z40C8BubYpO9" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.2 Use of Estimates and Assumptions</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140683 usd
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
75000000 shares
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
28694 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
23444 usd
CY2021Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
28694 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
40597 usd
CY2023Q2 jmkj Accounts Payable Related Party
AccountsPayableRelatedParty
10750 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
140683 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114183 usd
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.21 pure
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
29543 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
23978 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-29543 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-23978 usd
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35 pure
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
49239 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
39964 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49239 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39964 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
140683 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2,500-to-1

Files In Submission

Name View Source Status
0001017386-23-000275-index-headers.html Edgar Link pending
0001017386-23-000275-index.html Edgar Link pending
0001017386-23-000275.txt Edgar Link pending
0001017386-23-000275-xbrl.zip Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jmkj-20230630.xsd Edgar Link pending
jmkj_2023jun30-10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jmkj-20230630_cal.xml Edgar Link unprocessable
jmkj-20230630_def.xml Edgar Link unprocessable
jmkj-20230630_lab.xml Edgar Link unprocessable
jmkj-20230630_pre.xml Edgar Link unprocessable
jmkj_2023jun30-10q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending